Startup profile · funding coverage
Recursion funding, valuation and investors
Techbio company using automated labs and ML for drug discovery at scale.
Keep track of Recursion
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$60M · 2017
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$73M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Salt Lake City, Utah, USA
Investors in latest funding
Other: Menlo Ventures
Overview
Recursion Pharmaceuticals combines automated wet labs, imaging, and machine learning to map biology and discover drug candidates across dozens of disease areas. Founded by Chris Gibson and Dean Li in 2013, Utah-based Recursion went public on NASDAQ (RXRX) in April 2021. Early rounds included Lux Capital Series A ($13M, 2016) and DCVC-led Series B ($60M, 2017) with Menlo, CRV, and Two Sigma participating.
Why Recursion is interesting
Lux and DCVC backed phenomics platform to NASDAQ: RXRX (2021 IPO) — a16z portfolio overlap via early techbio cap table before public markets.
Product & use cases
Recursion OS captures cellular imaging data at scale, builds biological maps with ML, and prioritizes drug candidates for internal pipeline and pharma partnerships.
- Phenotypic drug discovery across rare and common diseases
- Partnership pipelines with Bayer, Roche, others
- AI-driven target identification from imaging
- Automated lab iteration reducing manual screening
Key facts
- IPO (Apr 2021): NASDAQ RXRX
- Series B (2017): $60M led by DCVC
- Automated phenomics platform at industrial scale
- Multiple pharma partnerships
Funding history (newest first)
Series B
2017 $60MSource: https://techcrunch.com/2017/07/13/recursion-pharmaceuticals-series-b/
Investors in our directory
Funds linked from Recursion's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Industrial-scale imaging dataset and automated lab loop — capital-intensive moat vs single-assay biotechs.
Techbio public markets volatile; Recursion must convert maps to clinical proof. Partnership revenue helps fund broad pipeline.
-
Insitro adjacent
ML drug discovery with different data modalities.
-
Exscientia direct
AI-designed drugs; public company path.
-
Traditional pharma HTS incumbent
Manual screening labs.
Notable stories
- Recursion pitched 'Google Maps of biology' — imaging every perturbation to build searchable cellular behavior database.
Industries
Market / IPO context
Ticker: RXRX (NASDAQ)
IPO status: public
IPO date: 2021-04-16
Editorial / static context — not a live quote.
FAQs about Recursion
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.